Exonbio has developed SARS-CoV-2 Nucleocapsid recombinant monoclonal antibodies for the global IVD and research communities in support of efforts to combat the pandemic. The SARS–CoV–2 nucleocapsid (N) protein is highly homologous to the N protein of SARS–CoV, which is essential for viral RNA replication and packaging into new virions. By using Exonbio’s SPIN® technology platform, highly specific antibodies from plasma cells are generated against nucleocapsid protein of SARS-CoV-2. The recombinant nucleocapsid antibodies developed has no cross reactivity to human coronavirus nucleocapsid protein.
SARS-CoV-2 N-protein IgG mAbs
|Clone ID||Isotype||Species||EC50 (ng/ml)|
Please reach out to us at email@example.com for more information about our SARS-CoV-2 Nucleocapsid protein monoclonal antibodies.
High-affinity monoclonal antibodies that fall in different epitope bins allow for antibody pairing for the development of ELISA kit. For detailed Nucleocapsid mAb pairing & clone information contact us.
ELISA: Nucleocapsid protein IgG mAbs are high affinity, with EC50 range between 0.5-3.5 ng/ml.
Biacore 3000: Crude supernatants containing rabbit monoclonal anti-NP antibodies were captured on protein A chip and nucleocapsid protein was injected at concentration of 300nM.